Renaissance Technologies’s Aptevo Therapeutics APVO Stock Holding History

Renaissance Technologies’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3	Closed	-$6.58K	–	3553
2024 Q3	$6.58K	Buy	+3	New	+$13.8K	﹤0.01%	3474
2024 Q1	–	Sell	-1	Closed	-$94K	–	3684
2023 Q4	$94K	Buy	+1	New	+$142K	﹤0.01%	3315
2023 Q3	–	Hold	0	–	–	–	3374
2023 Q2	–	Hold	0	–	–	–	3435
2023 Q1	–	Hold	0	–	–	–	3454
2022 Q4	–	Hold	0	–	–	–	3501
2022 Q3	–	Hold	0	–	–	–	3364
2022 Q2	–	Hold	0	–	–	–	3548
2022 Q1	–	Hold	0	–	–	–	3404
2021 Q4	–	Hold	0	–	–	–	3038
2021 Q3	–	Hold	0	–	–	–	2011
2021 Q2	–	Hold	0	–	–	–	1846
2021 Q1	–	Hold	0	–	–	–	1502
2020 Q4	–	Hold	0	–	–	–	1220
2020 Q3	–	Hold	0	–	–	–	2066
2020 Q2	–	Hold	0	–	–	–	2213
2020 Q1	–	Hold	0	–	–	–	2616
2019 Q4	–	Hold	0	–	–	–	2431
2019 Q3	–	Hold	0	–	–	–	2498
2019 Q2	–	Hold	0	–	–	–	2511
2019 Q1	–	Hold	0	–	–	–	2620
2018 Q4	–	Hold	0	–	–	–	2260
2018 Q3	–	Hold	0	–	–	–	1635
2018 Q2	–	Hold	0	–	–	–	1700
2018 Q1	–	Hold	0	–	–	–	2222
2017 Q4	–	Hold	0	–	–	–	2394
2017 Q3	–	Hold	0	–	–	–	3008
2017 Q1	–	Hold	0	–	-$47K	–	3209
2016 Q4	–	Hold	0	–	–	–	3166
2016 Q3	–	Hold	0	–	–	–	2726

Other funds holding APVO

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Center for Financial Planning Southfied, Michigan $1.08B AUM 12.2% 1-Year Est. Return

Renaissance Technologies's APVO Position: Q4 2024 in Review

Renaissance Technologies sold out of Aptevo Therapeutics (APVO) in Q4 2024, closing a stake of 3 shares — an estimated $6.58K sold.

Renaissance Technologies first reported a position in APVO in Q4 2023 and held it in 2 quarters. The position peaked at $94K in Q4 2023. 7 funds tracked by Wall St. Rank hold APVO as of Q4 2024.

Renaissance Technologies reported no remaining Aptevo Therapeutics position as of Q4 2024 after selling out during the quarter.
Renaissance Technologies sold 3 Aptevo Therapeutics shares in Q4 2024, an estimated $6.58K.
Renaissance Technologies first reported a position in Aptevo Therapeutics in Q4 2023 and held it in 2 quarters.
Renaissance Technologies's Aptevo Therapeutics position peaked at $94K in Q4 2023.
7 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.